Deferred Tax Assets, Operating Loss Carryforwards of ARROWHEAD PHARMACEUTICALS, INC. from 30 Sep 2013 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.
Summary
ARROWHEAD PHARMACEUTICALS, INC. quarterly Deferred Tax Assets, Operating Loss Carryforwards in USD history and change rate from 30 Sep 2013 to 30 Sep 2025.
  • ARROWHEAD PHARMACEUTICALS, INC. Deferred Tax Assets, Operating Loss Carryforwards for the quarter ending 30 Sep 2025 was $70,858,000, a 31% decline year-over-year.
Source SEC data
View on sec.gov
Deferred Tax Assets, Operating Loss Carryforwards, Quarterly (USD)
Deferred Tax Assets, Operating Loss Carryforwards, YoY Quarterly Change (%)

ARROWHEAD PHARMACEUTICALS, INC. Quarterly Deferred Tax Assets, Operating Loss Carryforwards (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $70,858,000 -$31,858,000 -31% 30 Sep 2025 10-K 25 Nov 2025 2025 FY
Q3 2024 $102,716,000 +$42,221,000 +70% 30 Sep 2024 10-K 25 Nov 2025 2025 FY
Q3 2023 $60,495,000 -$110,824,000 -65% 30 Sep 2023 10-K 26 Nov 2024 2024 FY
Q3 2022 $171,319,000 -$14,112,000 -7.6% 30 Sep 2022 10-K 29 Nov 2023 2023 FY
Q3 2021 $185,431,000 +$34,424,000 +23% 30 Sep 2021 10-K 28 Nov 2022 2022 FY
Q3 2020 $151,007,000 +$45,634,429 +43% 30 Sep 2020 10-K 22 Nov 2021 2021 FY
Q3 2019 $105,372,571 -$8,770,170 -7.7% 30 Sep 2019 10-K 23 Nov 2020 2020 FY
Q3 2018 $114,142,741 -$17,977,096 -14% 30 Sep 2018 10-K 25 Nov 2019 2019 FY
Q3 2017 $132,119,837 +$6,998,880 +5.6% 30 Sep 2017 10-K 11 Dec 2018 2018 FY
Q3 2016 $125,120,957 +$36,154,989 +41% 30 Sep 2016 10-K 12 Dec 2017 2017 FY
Q3 2015 $88,965,968 +$46,697,442 +110% 30 Sep 2015 10-K 14 Dec 2016 2016 FY
Q3 2014 $42,268,526 -$9,864,509 -19% 30 Sep 2014 10-K 14 Dec 2015 2015 FY
Q3 2013 $52,133,035 30 Sep 2013 10-K 25 Nov 2014 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.